Traumatic Optic Neuropathy
Traumatic Optic Neuropathy (TON) is a condition in which acute injury to the optic nerve from direct or indirect trauma results in vision loss.
- 1 Etiology
- 2 Risk Factors
- 3 General Pathology
- 4 Primary prevention
- 5 Diagnosis
- 6 Management
- 7 Additional Resources
- 8 References
Etiology[edit | edit source]
The most common cause of TON is indirect injury to the optic nerve, which is thought to be the result of transmitted shock from an orbital impact to the intracanalicular portion of optic nerve. Direct TON can result from penetrating injury or from bony fragments in the optic canal or orbit piercing the optic nerve. Orbital hemorrhage and optic nerve sheath hematoma can also cause TON by direct compression.
Risk Factors[edit | edit source]
There are no known risk factors for TON. In the International Optic Nerve Trauma Study, 85% of patients with indirect TON were male and the average age of patients with TON was 34. The most common mechanisms of injury were motor vehicle accident, bike accident, fall and assault.
General Pathology[edit | edit source]
The exact pathology of indirect TON is not well understood. The optic nerve dura is continuous with the orbital periosteum, leaving the optic nerve susceptible to transmission of force from blunt head trauma, particularly that affecting the superior orbital rim. Indirect TON has been hypothesized to result from shearing injury to the intracanalicular portion of optic nerve, which can cause axonal injury or disturb the blood supply of the optic nerve. It has also been suggested that the optic nerve may swell in the optic canal after trauma resulting in increased luminal pressure and secondary ischemic injury. Direct TON is presumed to be the result of tissue disruption secondary to foreign body or bony fragments impacting on the optic nerve.
Primary prevention[edit | edit source]
There is no primary prevention for TON.
Diagnosis[edit | edit source]
The diagnosis of TON is made clinically based on history and ophthalmic signs. Like other optic neuropathies, patients with TON may have decreased central visual acuity, decreased color vision, an afferent pupillary defect and/or visual field deficits. It is important to remember that albeit rare, TON can be bilateral, so an afferent pupillary defect may not be seen in patients with bilateral injury and vision loss. The optic nerve head will appear normal initially, but optic atrophy can be seen 3-6 weeks after the initial traumatic event.
History[edit | edit source]
A history consistent with TON would be vision loss after blunt or penetrating trauma that could not be explained by slit lamp or dilated fundus findings. Often these patients complain of acute unilateral decrease in vision, color vision deficits, or visual field deficits. The history and subjective complaints may be delayed due to the impact of and treatment for other concomitant head inuries or other systemic comorbidities.
Physical examination[edit | edit source]
The initial external eye exam may show signs of orbital trauma or fracture (soft tissue edema, hematoma, step-off on palpation of orbital rim). Decreased visual acuity and an afferent pupillary defect (in unilateral cases) are also seen. On funduscopy, the initial optic nerve head assessment will be normal. Optic atrophy may be seen 3-6 weeks after trauma.
Signs[edit | edit source]
- Decreased Vision
- Decreased color vision (Dyschromatopsia)
- Afferent pupillary defect
- Visual field deficits
Symptoms[edit | edit source]
- Blurry vision
- Decreased color sensation
Clinical diagnosis[edit | edit source]
The clinical diagnosis of TON is made on the basis of a specific constellation of history and physical exam findings. Patients have a history of trauma, and complain of or are found to have significant visual loss, decreased color vision, visual field deficit, an afferent papillary defect, and a dilated fundus exam without findings to explain these signs.
Diagnostic procedures[edit | edit source]
The diagnosis of TON is primarily clinical. There are some tests that can aid in the management and diagnosis of TON. It is important to obtain neuroimaging, usually a CT to visualize the optic nerve as well as the optic canal. The optic canal must be carefully evaluated for evidence of fracture. This can help assess for compression of the optic nerve by a hematoma or bony fragments impinging on the optic nerve, which would require surgical intervention. Automated visual field testing such as a Humphrey (HVF) can be usually to characterize visual field defects/scotomas in patients with TON over time. Finally, a VEP can be used to characterize the electrical activity of the optic nerve.
Laboratory test[edit | edit source]
There are no laboratory tests to aid in the diagnosis of TON.
Differential diagnosis[edit | edit source]
- Posterior ischemic optic neuropathy
- Optic neuritis
- Optic nerve avulsion
- Non-organic vision loss
- Pre-/intra-/subretinal hemorrhage
- Choroidal Rupture
- Commotio retinae
Management[edit | edit source]
The management of TON is controversial, however, the data in the literature to date has not shown any treatment to be superior to observation.
Medical therapy[edit | edit source]
Some authors have supported the use of high or “mega” dose corticosteroids in TON. This therapeutic regimen has been extrapolated from the National Acute Spinal Cord Injury Study II, which showed a statistically significant improvement in neurologic outcome (motor and sensory) in a subgroup analysis of acute spinal cord injury patients receiving a methyprednisolone 30 mg/kg bolus within eight hours of injury, followed by 5.4 mg/kg/hr for 23 hours,. Subsequently however,the CRASH (Corticosteroid Randomization After Significant Head injury) study showed an increased relative risk of death in patients given this regimen after significant head injury. The International Optic Nerve Trauma Study also did not show a difference in final visual acuity between patients with TON that were observed compared with those given steroids. Mouse models have shown promising results with the use of resveratrol after optic nerve crush injury. 
Surgery[edit | edit source]
Surgical intervention for TON was shown to not be beneficial in The International Optic Nerve Trauma Study. Some have supported the use of surgery in certain scenarios such as when a bony fragment is abutting to optic nerve or in the case of an optic nerve sheath hematoma but there is no good data supporting surgery for indirect TON.
Complications[edit | edit source]
Serious surgical complications specific to decompression surgery for TON include infection (meningitis), CSF leaks, and exacerbation of traumatic optic neuropathy. Complications from high or “mega” dose steroids include wound infection and GI bleed.
Prognosis[edit | edit source]
In the International Optic Nerve Trauma Study, visual acuity improvement of >3 lines was seen in 57% of the untreated group, 52% of the group that received steroids alone, and 32% of the group that underwent surgery. This was not a statistically significant result.
Additional Resources[edit | edit source]
- Yu Wai Man P, Griffiths PG. Surgery for traumatic optic neuropathy. Cochrane Database Syst Rev. 2005 Oct 19;(4).
- Yu-Wai-Man P, Griffiths PG. Steroids for traumatic optic neuropathy. Cochrane Database Syst Rev. 2011 Jan 19;(1).
- American Academy of Ophthalmology. Neuro-Ophthalmology/Orbit: Traumatic optic neuropathy Practicing Ophthalmologists Learning System, 2017 - 2019 San Francisco: American Academy of Ophthalmology, 2017.
References[edit | edit source]
- Levin, L.A., et al., The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology, 1999. 106(7): p. 1268-77.
- Young, W., NASCIS. National Acute Spinal Cord Injury Study. J Neurotrauma, 1990. 7(3): p. 113-4.
- Edwards, P., et al., Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet, 2005. 365(9475): p. 1957-9.
- Zuo, et al. SIRT1 promotes RGC survival and delays loss of function following optic nerve crush. Invest Ophthalmol Vis Sci. 2013 26;54(7):5097-102